NE NEWS SERVICE
AHMEDABAD, GUWAHATI, APRIL 29
Ahmedabad-based pharmaceutical company Hester Biosciences Limited on Wednesday announced a collaboration with Indian Institute of Technology Guwahati (IIT-G) to develop a vaccine against coronavirus (COVID-19). The agreement between the two parties was signed on April 15, a company release said.
The vaccine is expected to be ready by the end of this year for animal studies. The work is currently in its early stage of development, IITG said in a statement.
The vaccine will be based on a recombinant avian paramyxovirus based vector platform. The recombinant avian paramyxovirus-1 will be used to express the immunogenic protein of SARS-CoV-2 virus.
The recombinant avian paramyxovirus-1 expressing the SARS-CoV-2 protein could be used as a vaccine candidate for further study, the Institute said.
The team at IIT Guwahati is headed by Dr. Sachin Kumar, Associate Professor, Department of Biosciences and Bioengineering.
“It is too early to comment on the efficacy and immunogenicity of the vaccine, however, we will be able to reveal more details about this vaccine after the results of animal studies are obtained,” said researcher Dr Sachin Kumar, Associate Professor, Department of Biosciences and Bioengineering, IIT Guwahati.
According to the Institute, the avian paramyxovirus-1 has been explored as a vaccine vector for various animals and human pathogens.
The avian paramyxovirus-1 has been used to express the immunogenic protein of human pathogens such as HIV, avian influenza virus, human parainfluenza virus, SARS-CoV.
Similarly, it has also been explored as a vaccine vector for animal pathogens such as infectious bursal disease virus, infectious laryngotracheitis virus, bovine herpes virus, Nipah virus etc.
The research team has generated the recombinant avian paramyxovirus-1 based vaccine flatform for classical swine fever and Japanese encephalitis. The role of the Institute is to produce the recombinant vaccine candidate.
“IITG and Hester have collaborated to develop and manufacture a recombinant vaccine against COVID-19 disease as a preventive measure. Hester’s involvement would be from master seed development up to release of the commercial vaccine,” said Rajiv Gandhi, CEO, and MD, Hester Biosciences Limited.
He further added, “Hester has 23 years of experience in vaccine manufacturing on the veterinary side. It manufactures vaccines by using fermentation, tissue culture, continuous cell line, and chick embryo origin methods. Hester is also currently working towards developing next-generation recombinant poultry vaccines. Being in veterinary vaccine manufacturing, as well as working towards developing recombinant vaccines, Hester has a fairly good understanding and the capability to get into human vaccines, specifically into a vaccine against the COVID-19 disease.”
Prof. T. G. Sitharam, Director, IIT Guwahati, is hopeful that the outcome of this important collaboration will be a win-win situation for the country and will lead to breakthrough results in prevention of COVID-19 as well as provide leads for vaccine developments against other diseases as well in immediate future.
